Skip to main content
. 2012 Sep 22;13:173. doi: 10.1186/1745-6215-13-173

Table 1.

Common dimensions in intervention ensembles

 
Examples
Cetuximab
Belimumab
Gene transfer for AID-SCID
Treatment dimension  
Dose
mg/kg; cells; vector particles…
250 mg/m2
10 mg/kg
≥8 × 10^6 cells
Schedule
Daily; 4× weekly w/2 wk holidays…
Weekly until disease progression
3× @ 2-wk intervals; 4-wk intervals after
 
Administration/target
Infusion; oral; intratumoral…
Intravenous infusion
Intravenous infusion
Intravenous infusion
Co-intervention
Radiotherapy; immunosuppresion…
 
Standard of care
Non-myeloablative conditioning
Risk mitigation
Cardiac monitoring; liver enzymes…
Serum electrolytes monitoring
Monitor patients for hypersensitivity
 
Timing delivery
Symptom onset; 12 h after event…
After irinotecan or oxaliplatin failure
 
3 weeks after stopping PEG-ADA
Population dimensions
Diagnostic criteria
Marker positivity; diagnostic score…
KRAS mutation in codon 12 or 13
α-nuclear Ab titer ≥ 1:80 and/or α-dsDNA
 
Contraindications
Concurrent infection; clothing disorder…
 
Prior anaphylaxis to belimumab
Neutralizing Abs to vector (AAV8)
Indications
Disease; injury; at-risk population…
Metastatic colorectal cancer
Active systemic lupus erythematosus (SLE)
ADA-SCID
Age
 
Adults
Non-geriatric adults
Children
Outcome dimensions
Endpoint
Change on scale; time to event…
Survival
SLE responder index
Immune system reconstitution
Duration Short term; ‘long term’ remission…   1 year Permanent